These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37660747)

  • 1. Tackling TNF-α in autoinflammatory disorders and autoimmune diseases: From conventional to cutting edge in biologics and RNA- based nanomedicines.
    Andretto V; Dusi S; Zilio S; Repellin M; Kryza D; Ugel S; Lollo G
    Adv Drug Deliv Rev; 2023 Oct; 201():115080. PubMed ID: 37660747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases.
    Lopetuso LR; Cuomo C; Mignini I; Gasbarrini A; Papa A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.
    Ostrov BE
    Immunol Invest; 2015; 44(8):777-802. PubMed ID: 26575464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insight of Engineered Nano-based Biologics Approaches used to Combat Autoimmune Disease using TNF-α & IL Inhibitors.
    Patil D; Ajazuddin ; Bhattacharya S
    Curr Top Med Chem; 2023; 23(19):1793-1806. PubMed ID: 36999698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment.
    Havnaer A; Han G
    Am J Clin Dermatol; 2019 Aug; 20(4):539-564. PubMed ID: 30997665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond biologics: advanced therapies in inflammatory bowel diseases.
    Caio G; Lungaro L; Chiarioni G; Giancola F; Caputo F; Guarino M; Volta U; Testino G; Pellicano R; Zoli G; DE Giorgio R
    Minerva Gastroenterol (Torino); 2022 Sep; 68(3):319-332. PubMed ID: 34309337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-α inhibitor-related autoimmune disorders.
    De Stefano L; Pallavicini FB; Mauric E; Piccin V; Vismara EM; Montecucco C; Bugatti S
    Autoimmun Rev; 2023 Jul; 22(7):103332. PubMed ID: 37062440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of TNF-α and anti-TNF-α agents in the immunopathogenesis and management of immune dysregulation in primary immunodeficiency diseases.
    Abubakar SD; Ihim SA; Farshchi A; Maleknia S; Abdullahi H; Sasaki T; Azizi G
    Immunopharmacol Immunotoxicol; 2022 Apr; 44(2):147-156. PubMed ID: 35296212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease.
    Nakase H
    Gut Liver; 2020 Jan; 14(1):7-19. PubMed ID: 30919602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions.
    Eder P; Zielińska A; Karczewski J; Dobrowolska A; Słomski R; Souto EB
    J Nanobiotechnology; 2021 Oct; 19(1):346. PubMed ID: 34715852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting cytokines to treat autoinflammatory diseases.
    Hausmann JS
    Clin Immunol; 2019 Sep; 206():23-32. PubMed ID: 30394352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines.
    Kim EY; Moudgil KD
    Cytokine; 2017 Oct; 98():87-96. PubMed ID: 28438552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?
    Anjie SI; Hulshoff MS; D'Haens G
    Expert Opin Biol Ther; 2023 Apr; 23(4):341-351. PubMed ID: 37010030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From the updated landscape of the emerging biologics for IBDs treatment to the new delivery systems.
    Yang J; Li D; Zhang M; Lin G; Hu S; Xu H
    J Control Release; 2023 Sep; 361():568-591. PubMed ID: 37572962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: a meta-analysis.
    Antonatos C; Stavrou EF; Evangelou E; Vasilopoulos Y
    Pharmacogenomics; 2021 May; 22(7):435-445. PubMed ID: 33887993
    [No Abstract]   [Full Text] [Related]  

  • 16. The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies.
    Glaser RL; Goldbach-Mansky R
    Curr Allergy Asthma Rep; 2008 Jul; 8(4):288-98. PubMed ID: 18606080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Switching to biological agents in autoimmune and autoinflammatory disorders: current targets and therapy.
    Gasparyan AY
    Curr Med Chem; 2015; 22(16):1890-1. PubMed ID: 25693591
    [No Abstract]   [Full Text] [Related]  

  • 18. Study of tumor necrosis factor receptor in the inflammatory bowel disease.
    Souza RF; Caetano MAF; Magalhães HIR; Castelucci P
    World J Gastroenterol; 2023 May; 29(18):2733-2746. PubMed ID: 37274062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits and Risks Associated With Continuation of Anti-Tumor Necrosis Factor After 24 Weeks of Pregnancy in Women With Inflammatory Bowel Disease : A Nationwide Emulation Trial.
    Meyer A; Neumann A; Drouin J; Weill A; Carbonnel F; Dray-Spira R
    Ann Intern Med; 2022 Oct; 175(10):1374-1382. PubMed ID: 36162111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence.
    Zhang M; Bai X; Cao W; Ji J; Wang L; Yang Y; Yang H
    Front Immunol; 2021; 12():677957. PubMed ID: 34335579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.